Cellular deficiency in the RGS10 protein facilitates chemoresistant ovarian cancer

Future Med Chem. 2015 Aug;7(12):1483-9. doi: 10.4155/fmc.15.81. Epub 2015 Aug 21.

Abstract

More than 30 regulators of G protein signaling (RGS) proteins encompass the RGS protein superfamily of critical regulators essential to cellular homeostasis. There is enormous structural and functional diversity among the RGS superfamily, and as such they serve a wide range of functions in regulating cell biology and physiology. Recent evidence has suggested roles for multiple RGS proteins in cancer initiation and progression, which has prompted research toward the potential modulation of these proteins as a new approach in cancer therapy. This article will discuss basic RGS molecular pharmacology, summarize the cellular functions and epigenetic regulation of RGS10, review ovarian cancer chemotherapy and describe the role of RGS10 in ovarian cancer survival signaling.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / therapeutic use
  • Drug Resistance, Neoplasm*
  • Epigenesis, Genetic
  • Female
  • GTP-Binding Proteins / metabolism
  • Gene Expression Regulation, Neoplastic*
  • Humans
  • Ovarian Neoplasms / drug therapy*
  • Ovarian Neoplasms / genetics*
  • Ovarian Neoplasms / metabolism
  • Ovarian Neoplasms / pathology
  • Ovary / drug effects*
  • Ovary / metabolism
  • Ovary / pathology
  • RGS Proteins / analysis
  • RGS Proteins / genetics*
  • RGS Proteins / metabolism

Substances

  • Antineoplastic Agents
  • RGS Proteins
  • RGS10 protein, human
  • GTP-Binding Proteins